New research presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that the proportion of ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial ...

Obesity is on the rise. Among U.S. adults aged 20 or older, 4 in 10 met the criteria for obesity in the most recent National Health and Nutrition Examination Survey, up from roughly 3 in 10 two ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

New evidence suggests that factors other than the percentage of weight loss should be considered when determining the success ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

CNIO researchers found that in mice on high-fat diets, cancer cells in the bloodstream use platelets as a protective shield, ...

A recent study, published in the scientific journal Nature Metabolism and led by the German Center for Diabetes Research (DZD ...

Note – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.* New research to be presented at this year ...